Background: Millions of children in the United States have been infected with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), with many infections leading to …

OBJECTIVES: Remdesivir shortens time to recovery in adults with severe coronavirus
disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe …

Despite 3.5 years of the SARS-CoV-2 pandemic, we still lack effective drugs against COVID-
19. The first and most widely used drug, remdesivir, has not yet been shown to be effective …

OBJECTIVES Remdesivir decreases the risk of SARS-CoV-2 infection progressing to severe
disease in adults. This study evaluated remdesivir safety and pharmacokinetics in infants …

Introduction While most children experience mild coronavirus disease 2019 (COVID-19)
infections, a minority of cases progress to severe or critical illness. This study aimed to …

Abstract Background and Aims There is a paucity of information on remdesivir (RDV) use in
severe pediatric coronavirus disease 2019 (COVID‐19). We aimed to explore the …

Clinical efficacy of remdesivir in children with COVID-19 is unclear. This propensity-score-
matched retrospective cohort study of children with COVID-19 showed that the rate of …

Children represent a minority of total COVID-19 cases, but studies have reported severe
disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated …

Abstract Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-COV-2) virus, has spread worldwide since 2019. Several …

Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most
children, a small proportion develop severe or critical illness. Data describing agents with …